keyword
https://read.qxmd.com/read/37205634/proteasome-inhibition-sensitizes-liposarcoma-to-mdm2-inhibition-with-nutlin-3-by-activating-the-atf4-chop-stress-response-pathway
#21
JOURNAL ARTICLE
Michael P Ludwig, Matthew D Galbraith, Neetha Paul Eduthan, Amanda A Hill, Michael R Clay, Cristiam Moreno Tellez, Breelyn A Wilky, Anthony Elias, Joaquín Maximiliano Espinosa, Kelly D Sullivan
Liposarcoma is the most commonly occurring soft tissue sarcoma and is frequently characterized by amplification of chromosome region 12q13-15 harboring the oncogenes MDM2 and CDK4. This unique genetic profile makes liposarcoma an attractive candidate for targeted therapeutics. While CDK4/6 inhibitors are currently employed for treatment of several cancers, MDM2 inhibitors have yet to attain clinical approval. Here, we report the molecular characterization of the response of liposarcoma to the MDM2 inhibitor nutlin-3...
May 19, 2023: Cancer Research
https://read.qxmd.com/read/37012334/early-activation-of-cellular-stress-and-death-pathways-caused-by-cytoplasmic-tdp-43-in-the-rnls8-mouse-model-of-als-and-ftd
#22
JOURNAL ARTICLE
Wei Luan, Amanda L Wright, Heledd Brown-Wright, Sheng Le, Rebecca San Gil, Lidia Madrid San Martin, Karen Ling, Paymaan Jafar-Nejad, Frank Rigo, Adam K Walker
TAR DNA binding protein 43 (TDP-43) pathology is a key feature of over 95% of amyotrophic lateral sclerosis (ALS) and nearly half of frontotemporal dementia (FTD) cases. The pathogenic mechanisms of TDP-43 dysfunction are poorly understood, however, activation of cell stress pathways may contribute to pathogenesis. We, therefore, sought to identify which cell stress components are critical for driving disease onset and neurodegeneration in ALS and FTD. We studied the rNLS8 transgenic mouse model, which expresses human TDP-43 with a genetically-ablated nuclear localisation sequence within neurons of the brain and spinal cord resulting in cytoplasmic TDP-43 pathology and progressive motor dysfunction...
April 3, 2023: Molecular Psychiatry
https://read.qxmd.com/read/36969743/pharmaceutical-reactivation-of-attenuated-apoptotic-pathways-leads-to-elimination-of-osimertinib-drug-tolerant-cells
#23
JOURNAL ARTICLE
Matthew J Martin, Nicolas Floc'h, Matthias Pfeifer, Steven Criscione, Oona Delpuech, Sladjana Gagrica, Yi Yao, Ultan McDermott, Paul D Smith
UNLABELLED: Osimertinib is an EGFR tyrosine kinase inhibitor (TKI) with proven clinical efficacy; however, acquired resistance presents an obstacle to curing EGFR -driven disease. Recent studies have shown that drug-tolerant persister cells (DTP) have a distinct transcriptional profile that may confer specific vulnerabilities. By definition these cells avoid apoptosis, yet little is known about how their survival is regulated. We found that paradoxically, the proapoptotic gene BIM was upregulated in osimertinib DTPs, and cotreatment with BH3 mimetics could trigger DTP cell death...
October 2022: Cancer Res Commun
https://read.qxmd.com/read/36763538/bh3-profiling-identifies-bcl-2-dependence-in-adult-patients-with-early-t-cell-progenitor-acute-lymphoblastic-leukemia
#24
JOURNAL ARTICLE
Elyse A Olesinski, Karanpreet S Bhatia, Aarthi Nivasini Mahesh, Shazwina Rosli, Jameelah S Mohamed, Wei Ying Jen, Nitin Jain, Jacqueline S Garcia, Gee Chuan Wong, Melissa G Ooi, Anthony Letai, Marina Y Konopleva, Shruti Bhatt
No abstract text is available yet for this article.
February 10, 2023: Blood Advances
https://read.qxmd.com/read/36717906/potent-hepatoprotective-activity-of-common-rattan-calamus-rotang-l-leaf-extract-and-its-molecular-mechanism
#25
JOURNAL ARTICLE
Walaa S Anwar, Fatma M Abdel-Maksoud, Ahmed M Sayed, Iman A M Abdel-Rahman, Makboul A Makboul, Ahmed M Zaher
BACKGROUND: Calamus rotang L. (CR) is an Indian shrub. The leaves and other organs of the plant are traditionally used in India for treatment of various diseases. The in vitro antioxidant property of the leaves extract was previously established. Thus, the current study aimed to evaluate the antioxidant and hepatoprotective effects of CR ethyl acetate extract at a dose of 350 mg/kg on CCl4 induced hepatotoxic rats through different mechanisms. METHODS: Histopathological examination of the treated rats' group in comparison with positive and negative controls were performed...
January 30, 2023: BMC complementary medicine and therapies
https://read.qxmd.com/read/36717653/a-phase-1b-study-of-ibrutinib-in-combination-with-obinutuzumab-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia
#26
RANDOMIZED CONTROLLED TRIAL
Christine E Ryan, Danielle M Brander, Paul M Barr, Svitlana Tyekucheva, Liam R Hackett, Mary C Collins, Stacey M Fernandes, Yue Ren, Yinglu Zhou, Mikaela M McDonough, Heather A Walker, Monica R McEwan, Jeremy S Abramson, Eric D Jacobsen, Ann S LaCasce, David C Fisher, Jennifer R Brown, Matthew S Davids
This study investigated ibrutinib plus obinutuzumab in relapsed/refractory CLL, evaluating tolerability of 3 sequencing regimens as well as overall safety and efficacy. Fifty-two patients were initially randomized 1:1:1 to receive either obinutuzumab 1 month before ibrutinib initiation, ibrutinib 1 month prior to obinutuzumab initiation, or to start both drugs concomitantly. Higher rates of infusion-related reactions were observed with the first sequence, and only the latter 2 cohorts were expanded. Grade 4 hematologic toxicity was uncommon, and notable all-grade non-hematologic toxicities included bruising (58%), hypertension (46%), arthralgia (38%), diarrhea (37%), transaminitis (35%), atrial fibrillation (21%), and serious infection (17%)...
April 2023: Leukemia
https://read.qxmd.com/read/36711707/-in-situ-architecture-of-opa1-dependent-mitochondrial-cristae-remodeling
#27
Michelle Y Fry, Paula P Navarro, Xingping Qin, Zintes Inde, Virly Y Ananda, Camila Makhlouta Lugo, Pusparanee Hakim, Bridget E Luce, Yifan Ge, Julie L McDonald, Ilzat Ali, Leillani L Ha, Benjamin P Kleinstiver, David C Chan, Kristopher A Sarosiek, Luke H Chao
UNLABELLED: Cristae membrane state plays a central role in regulating mitochondrial function and cellular metabolism. The protein Optic atrophy 1 (Opa1) is an important crista remodeler that exists as two forms in the mitochondrion, a membrane-anchored long form (l-Opa1) and a processed short form (s-Opa1). The mechanisms for how Opa1 influences cristae shape have remained unclear due to the lack of native 3D views of cristae morphology. We perform in situ cryo-electron tomography of cryo-focused ion beam milled mouse embryonic fibroblasts with well-defined Opa1 states to understand how each form of Opa1 influences cristae architecture...
January 18, 2023: bioRxiv
https://read.qxmd.com/read/36706751/peptides-from-human-bnip5-and-pxt1-and-non-native-binders-of-pro-apoptotic-bak-can-directly-activate-or-inhibit-bak-mediated-membrane-permeabilization
#28
JOURNAL ARTICLE
Fiona Aguilar, Stacey Yu, Robert A Grant, Sebastian Swanson, Dia Ghose, Bonnie G Su, Kristopher A Sarosiek, Amy E Keating
Apoptosis is important for development and tissue homeostasis, and its dysregulation can lead to diseases, including cancer. As an apoptotic effector, BAK undergoes conformational changes that promote mitochondrial outer membrane disruption, leading to cell death. This is termed "activation" and can be induced by peptides from the human proteins BID, BIM, and PUMA. To identify additional peptides that can regulate BAK, we used computational protein design, yeast surface display screening, and structure-based energy scoring to identify 10 diverse new binders...
January 23, 2023: Structure
https://read.qxmd.com/read/36622698/synthetic-lethal-interaction-with-bcl-xl-blockade-deepens-response-to-cetuximab-in-patient-derived-models-of-metastatic-colorectal-cancer
#29
JOURNAL ARTICLE
Simonetta M Leto, Martina Ferri, Francesco Sassi, Eugenia R Zanella, Francesca Cottino, Valentina Vurchio, Irene Catalano, Alessandro Ferrero, Caterina C Zingaretti, Caterina Marchiò, Elena Grassi, Livio Trusolino, Andrea Bertotti
PURPOSE: Approximately 20% of patients with RAS wild-type metastatic colorectal cancer (mCRC) experience objective responses to the anti-EGFR antibody cetuximab, but disease eradication is seldom achieved. The extent of tumor shrinkage correlates with long-term outcome. We aimed to find rational combinations that potentiate cetuximab efficacy by disrupting adaptive dependencies on antiapoptotic molecules (BCL2, BCL-XL, MCL1). EXPERIMENTAL DESIGN: Experiments were conducted in patient-derived xenografts (PDX) and organoids (PDXO)...
March 14, 2023: Clinical Cancer Research
https://read.qxmd.com/read/36585521/high-caspase-3-and-vulnerability-to-dual-bcl2-family-inhibition-define-eto2-glis2-pediatric-leukemia
#30
JOURNAL ARTICLE
Zakia Aid, Elie Robert, Cécile K Lopez, Maxence Bourgoin, Fabien Boudia, Melchior Le Mene, Julie Riviere, Marie Baille, Salima Benbarche, Laurent Renou, Alexandre Fagnan, Cécile Thirant, Laetitia Federici, Laure Touchard, Yann Lecluse, Anton Jetten, Birgit Geoerger, Hélène Lapillonne, Eric Solary, Muriel Gaudry, Soheil Meshinchi, Françoise Pflumio, Patrick Auberger, Camille Lobry, Arnaud Petit, Arnaud Jacquel, Thomas Mercher
Pediatric acute myeloid leukemia expressing the ETO2::GLIS2 fusion oncogene is associated with dismal prognosis. Previous studies have shown that ETO2::GLIS2 can efficiently induce leukemia development associated with strong transcriptional changes but those amenable to pharmacological targeting remained to be identified. By studying an inducible ETO2::GLIS2 cellular model, we uncovered that de novo ETO2::GLIS2 expression in human cells led to increased CASP3 transcription, CASP3 activation, and cell death...
December 30, 2022: Leukemia
https://read.qxmd.com/read/36521105/venetoclax-treatment-in-cancer-patients-has-limited-impact-on-circulating-t-and-nk-cells
#31
JOURNAL ARTICLE
Charis E Teh, Hongke Peng, Mengxiao Luo, Tania Tan, Marie Trussart, Lauren J Howson, Chong Chyn Chua, Christine Muttiah, Fiona C Brown, Matthew E Ritchie, Andrew H Wei, Andrew W Roberts, Vanessa L Bryant, Mary Ann Anderson, Geoffrey J Lindeman, David Ching Siang Huang, Rachel Thijssen, Daniel H D Gray
Venetoclax is an effective treatment for certain blood cancers, such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). However, most patients relapse while on venetoclax and further treatment options become limited. Combining venetoclax with immunotherapies is an attractive approach; however, a detailed understanding of how venetoclax treatment impacts normal immune cells in patients is lacking. In this study, we performed deep profiling of peripheral blood cells from CLL and AML patients before and after short-term treatment with venetoclax using mass cytometry (CyTOF) and found no impact on the concentrations of key T cell subsets nor their expression of checkpoint molecules...
December 15, 2022: Blood Advances
https://read.qxmd.com/read/36509415/expression-profile-and-molecular-function-of-beclin-1-in-epinephelus-akaara-in-response-to-immune-stimuli-and-oxidative-stress
#32
JOURNAL ARTICLE
Kishanthini Nadarajapillai, H M V Udayantha, Sarithaa Sellaththurai, T D W Kasthuriarachchi, Gaeun Kim, Jehee Lee
Beclin-1, the mammalian ortholog of the yeast autophagy-related gene 6 (Atg 6), is a key regulator of autophagy. A variety of health and disease conditions in mammals are intricately related to the broad spectrum of beclin-1 functions. Nevertheless, few studies have investigated the role of beclin-1 in fish. In this study, we identified and cloned the beclin-1 cDNA (EaBECN-1) of Epinephelus akaara (red-spotted grouper) and carried out in silico analysis, tissue-specific expression analysis, immune challenge experiment, and in vitro analysis of its roles against viral infection and oxidative stress...
December 9, 2022: Fish & Shellfish Immunology
https://read.qxmd.com/read/36456699/microfluidic-based-dynamic-bh3-profiling-predicts-anticancer-treatment-efficacy
#33
JOURNAL ARTICLE
Albert Manzano-Muñoz, José Yeste, María A Ortega, Fernando Martín, Anna López, Jordi Rosell, Sandra Castro, César Serrano, Josep Samitier, Javier Ramón-Azcón, Joan Montero
Precision medicine is starting to incorporate functional assays to evaluate anticancer agents on patient-isolated tissues or cells to select for the most effective. Among these new technologies, dynamic BH3 profiling (DBP) has emerged and extensively been used to predict treatment efficacy in different types of cancer. DBP uses synthetic BH3 peptides to measure early apoptotic events ('priming') and anticipate therapy-induced cell death leading to tumor elimination. This predictive functional assay presents multiple advantages but a critical limitation: the cell number requirement, that limits drug screening on patient samples, especially in solid tumors...
December 1, 2022: NPJ Precision Oncology
https://read.qxmd.com/read/36430230/navitoclax-most-promising-bh3-mimetic-for-combination-therapy-in-hodgkin-lymphoma
#34
JOURNAL ARTICLE
Myra Langendonk, Nienke A M Smit, Wouter Plattel, Arjan Diepstra, Tom van Meerten, Lydia Visser
The treatment of young patients with Hodgkin lymphoma (HL) is often successful but a significant proportion of patients suffers from late toxicity. In the current era there are new opportunities for less toxic and more targeted treatment options. In this respect, the anti-apoptotic pathway is an attractive target since Hodgkin tumor cells abundantly express components of this pathway. We measured the effect of BH3 mimetics that interfere with anti-apoptotic proteins in cell lines, also in combination with the standard of care chemotherapeutic doxorubicin and the recently discovered preclinically active tamoxifen...
November 9, 2022: International Journal of Molecular Sciences
https://read.qxmd.com/read/36279564/bcl-xl-is-a-key-mediator-of-apoptosis-following-krasg12c-inhibition-in-krasg12c-mutant-colorectal-cancer
#35
JOURNAL ARTICLE
Hajrah Khawaja, Rebecca Briggs, Cheryl H Latimer, Mustasin Rassel, Daryl Griffin, Lyndsey Hanson, Alberto Bardelli, Frederica Di Nicolantonio, Simon S McDade, Christopher J Scott, Shauna Lambe, Manisha Maurya, Andreas U Lindner, Jochen H M Prehn, Jose Sousa, Chris Winnington, Melissa J LaBonte, Sarah Ross, Sandra Van Schaeybroeck
Novel covalent inhibitors of KRASG12C have shown limited response rates in patients with KRASG12C-mutant (MT) colorectal cancer. Thus, novel KRASG12C inhibitor combination strategies that can achieve deep and durable responses are needed. Small-molecule KRASG12C inhibitors AZ'1569 and AZ'8037 were used. To identify novel candidate combination strategies for AZ'1569, we performed RNA sequencing, siRNA, and high-throughput drug screening. Top hits were validated in a panel of KRASG12CMT colorectal cancer cells and in vivo...
January 3, 2023: Molecular Cancer Therapeutics
https://read.qxmd.com/read/36048524/lisaftoclax-apg-2575-is-a-novel-bcl-2-inhibitor-with-robust-antitumor-activity-in-preclinical-models-of-hematologic-malignancy
#36
JOURNAL ARTICLE
Jing Deng, Aneel Paulus, Douglas D Fang, Alak Manna, Guangfeng Wang, Hengbang Wang, Saijie Zhu, Jianyong Chen, Ping Min, Yan Yin, Navnita Dutta, Nabanita Halder, Gina Ciccio, John A Copland, James Miller, Bing Han, Longchuan Bai, Liu Liu, Mi Wang, Donna McEachern, Sally Przybranowski, Chao-Yie Yang, Jeanne A Stuckey, Depei Wu, Caixia Li, Jeremy Ryan, Anthony Letai, Sikander Ailawadhi, Dajun Yang, Shaomeng Wang, Asher Chanan-Khan, Yifan Zhai
PURPOSE: Development of BCL-2-specific inhibitors poses unique challenges in drug design because of BCL-2 homology domain 3 (BH3) shared homology between BCL-2 family members and the shallow surface of their protein-protein interactions. We report herein discovery and extensive preclinical investigation of lisaftoclax (APG-2575). EXPERIMENTAL DESIGN: Computational modeling was used to design "lead" compounds. Biochemical binding, mitochondrial BH3 profiling, and cell-based viability or apoptosis assays were used to determine the selectivity and potency of BCL-2 inhibitor lisaftoclax...
September 1, 2022: Clinical Cancer Research
https://read.qxmd.com/read/35863479/screening-of-four-key-genes-in-esophageal-carcinoma-based-on-tcga-and-geo-data-and-verification-of-anti-proliferative-effect-of-laptm4b-knockdown-in-esophageal-carcinoma-cells-invitro
#37
JOURNAL ARTICLE
Kai Guo, Keyan Li
Esophageal carcinoma (ESCA) is one of the most prevalent and aggressive malignancies of the gastrointestinal tract and constitutes sixth primary cause of cancer-related death worldwide. It is urgently needed to identify effective therapeutic targets. Differentially expressed genes (DEGs) involved in ESCA were identified via bioinformatics analysis. Four DEGs were selected for further analysis using Gene Expression Profiling Interactive Analysis, Human Protein Atlas, UALCAN web portal, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis...
July 19, 2022: Archives of Biochemistry and Biophysics
https://read.qxmd.com/read/35787546/no-time-to-die-intrinsic-apoptosis-signaling-in-hematopoietic-stem-and-progenitor-cells-and-therapeutic-implications
#38
REVIEW
Florian Hagenbourger, Sheila Bohler, Miriam Erlacher
PURPOSE OF REVIEW: Dysregulated apoptosis contributes to the pathogenesis of many hematologic malignancies. BH3-mimetics, antagonists of antiapoptotic BCL-2 proteins, represent novel, and promising cancer drugs. While the acute myelosuppressive effects of Venetoclax, the first Food and Drug Administration approved BCL-2 inhibitor, are fairly well described, little is known about side effects of novel BH3-mimetics and effects of chronic Venetoclax treatment. RECENT FINDINGS: Highly relevant publications focused on the effects of acute and chronic Venetoclax therapy, with focus on cell-type specific adaptive mechanisms, the emergence of clonal hematopoiesis, and the selection of BAX-mutated hematopoietic cells in patients treated with Venetoclax for a long period...
July 1, 2022: Current Opinion in Hematology
https://read.qxmd.com/read/35752202/pro-apoptotic-complexes-of-bax-and-bak-on-the-outer-mitochondrial-membrane
#39
REVIEW
Philipp Wolf, Axel Schoeniger, Frank Edlich
In multicellular organisms the regulated cell death apoptosis is critically important for both ontogeny and homeostasis. Mitochondria are indispensable for stress-induced apoptosis. The BCL-2 protein family controls mitochondrial apoptosis and initiates cell death through the pro-apoptotic activities of BAX and BAK at the outer mitochondrial membrane (OMM). Cellular survival is ensured by the retrotranslocation of mitochondrial BAX and BAK into the cytosol by anti-apoptotic BCL-2 proteins. BAX/BAK-dependent OMM permeabilization releases the mitochondrial cytochrome c (cyt c), which initiates activation of caspase-9...
October 2022: Biochimica et Biophysica Acta. Molecular Cell Research
https://read.qxmd.com/read/35447071/augmenting-nk-cell-based-immunotherapy-by-targeting-mitochondrial-apoptosis
#40
JOURNAL ARTICLE
Rongqing Pan, Jeremy Ryan, Deng Pan, Kai W Wucherpfennig, Anthony Letai
Interest in harnessing natural killer (NK) cells for cancer immunotherapy is rapidly growing. However, efficacy of NK cell-based immunotherapy remains limited in most trials. Strategies to augment the killing efficacy of NK cells are thus much needed. In the current study, we found that mitochondrial apoptosis (mtApoptosis) pathway is essential for efficient NK killing, especially at physiologically relevant effector-to-target ratios. Furthermore, NK cells can prime cancer cells for mtApoptosis and mitochondrial priming status affects cancer-cell susceptibility to NK-mediated killing...
April 28, 2022: Cell
keyword
keyword
116347
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.